For example, since MiR-103 and MiR-107 have been shown to regulate insulin resistance and that antagomiR-mediated MiR-103/107 silencing significantly improves insulin sensitivity and glucose tolerance in obese mice [160], anti-miR-103/107 oligonucleotides (anti-miRs) are explored for the treatment of T2DM and NAFLD (e.g., phase I/IIA randomized clinical trial of antagomiR-103 and -107 in subjects with T2DM and NAFLD; ClinicalTrials.gov: NCT02826525). The gene discussed is INS; the disease is glucose measurement.